In multiple myeloma showdown, J&J adds another feather to Darzalex's cap
Sanofi’s Sarclisa burst onto the multiple myeloma scene last year to challenge J&J’s CD38 heavyweight Darzalex. But J&J isn’t going down without a fight, and now it’s touting another approval for the hard-to-treat blood cancer — along with an easier route of administration that could save patients hours of their time.
The FDA has given Darzalex Faspro the thumbs-up as a second-line treatment for adults with multiple myeloma in combination with pomalidomide and dexamethasone (Pd), Janssen said Monday. The approval marks the sixth indication for Darzalex Faspro, which is co-formulated with Halozyme’s recombinant human hyaluronidase PH20, a type of enzyme that catalyzes the degradation of hyaluronic acid.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.